Protheragen, a contract research organization (CRO) focused on preclinical drug development services, has launched a service offering focused on preclinical in vivo and in vitro pharmacokinetic (PK) evaluation of anti-obesity therapeutic drugs.

Developing a new obesity drug requires multiple steps: target validation, pharmacokinetic studies, safety assessments, and more. Protheragen Obesity is a Contract Research Organization (CRO) that provides exactly these services, with a focus on the preclinical stage.